Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan and Melphalan vs Melphalan for ASCT in Myeloma
NCT05636787Phase 2Recruiting
- Sponsor
- Insel Gruppe
- Start
- Jun 2023
- Primary completion
- Jan 2028
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan in multiple myeloma (MM), sponsored by Insel Gruppe. Started Jun 2023; status: recruiting.
02
Drugs
treosulfan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05636787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636787.